Related Experiment Videos
Adenovirus-mediated transfer of a p53 gene in ovarian cancer
1Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan.
Abstract:
Given the lack of effective conventional therapy, those patients with recurrent or refractory ovarian cancer should be considered for currently approved investigational gene therapy protocols. Several studies have shown a potential modality of p53 gene transfer in cancer gene therapy. We also developed a new recombinant adenovirus carrying a wild-type p53 gene (AxCAp53). Although the efficacy of AxCAp53 to suppression of cell growth was not sufficient, AxCAp53 increased sensitivity to CDDP in ovarian cancer cells with deletion of the p53 gene. The combination of CDDP and AxCAp53 may be a potential strategy for the therapy of CDDP resistant ovarian cancer.
Insights
Investigational gene therapy using p53 gene transfer, specifically AxCAp53, shows promise for treating refractory ovarian cancer. Combining this with CDDP may overcome cisplatin resistance in ovarian cancer patients.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Recurrent or refractory ovarian cancer lacks effective conventional treatments.
- Gene therapy, particularly p53 gene transfer, is an emerging modality for cancer treatment.
- The p53 tumor suppressor gene plays a critical role in cell cycle regulation and apoptosis.
Purpose of the Study:
- To evaluate the potential of a novel recombinant adenovirus carrying a wild-type p53 gene (AxCAp53) for ovarian cancer therapy.
- To investigate the efficacy of AxCAp53 in combination with cisplatin (CDDP) in overcoming drug resistance.
Main Methods:
- Development of a recombinant adenovirus vector, AxCAp53, for wild-type p53 gene delivery.
- Assessment of AxCAp53's efficacy in suppressing ovarian cancer cell growth.
- Evaluation of AxCAp53's ability to sensitize p53-deficient ovarian cancer cells to CDDP.
Main Results:
- AxCAp53 alone demonstrated insufficient efficacy in suppressing ovarian cancer cell growth.
- AxCAp53 significantly increased the sensitivity of p53-deleted ovarian cancer cells to CDDP.
- The combination therapy showed potential in overcoming CDDP resistance.
Conclusions:
- While AxCAp53 monotherapy has limitations, its combination with CDDP presents a promising strategy for treating cisplatin-resistant ovarian cancer.
- Investigational gene therapy protocols involving p53 gene transfer warrant consideration for patients with refractory ovarian cancer.